StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen KYPROLIS (carfilzomib by Quarter

KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide reported sales growth YoY (%) (%)

QuarterlyAnnual

Amgen KYPROLIS (carfilzomib: -17.0% in Q2 2026, down 17.0 pts from a year earlier. That is the lowest of the 32 quarters on record here.

Latest, Q2 2026
-17.0%
Period ended Jun 30, 2026
Change on a year earlier
-17.0 pts
0.0% in Q2 2025
History
32 quarters
Since Q3 2018
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| KYPROLIS ® | 201 | 113 | 314 | 378 | (17%)”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Product Sales Detail by Product and Geographic Region.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-17.0%-17.0 ptsForm 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20262.0%+16.0 ptsForm 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025-6.0%-12.0 ptsForm 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025-5.0%-13.0 ptsForm 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 20250.0%-9.0 ptsForm 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025-14.0%-19.0 ptsForm 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 20246.0%-2.0 ptsForm 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 20248.0%-2.0 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20249.0%0.0 ptsForm 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 20245.0%-20.0 ptsForm 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 20238.0%-6.0 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202310.0%+1.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 20239.0%-4.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202325.0%+11.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202214.0%+10.0 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 20229.0%-4.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Cite this data

StockData. (2026). Amgen KYPROLIS (carfilzomib (%), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kyprolis-yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.